301246.SHE Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A
- Market cap
- CNY 6.29B
- P/E
- 20.2x
- P/B
- 1.31x
- ROE
- 5.3%
- Dividend yield
- 0.45%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 301246.SHE undervalued?
Graham number301246.SHE trades 8.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A fundamental analysis
No fundamental analysis for Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A yet.
Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A
Hubei Hongyuan Pharmaceutical Technology Co., Ltd., together with its subsidiaries, produces and sells pharmaceutical products in China, Asia, Europe, Africa, the Americas and internationally. The company offers active pharmaceutical ingredients, such as metronidazole, benzoyl metronidazole, dimetrizole, and acyclovir; pharmaceutical intermediates, including imidazole, glyoxylic acid, 2-methyl imidazole, 2-methyl-5-nitroimidazole, sulfate, guanine, diacetyl guanine, and diac…
Full company profileHubei Hongyuan Pharmaceutical Technology Co. Ltd. A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 1.58B | 2.06B | 2.05B | 1.77B | 1.94B | 2.59B |
| Gross Profit | 531M | 481M | 267M | 216M | 364M | 510M |
| Operating Income | 375M | 330M | 110M | 86.1M | 178M | 307M |
| EBITDA | - | 575M | 269M | 250M | 362M | 324M |
| Net Income | 494M | 435M | 87.2M | 51.5M | 119M | 246M |
| EPS | 1.40 | 1.23 | 0.22 | 0.13 | 0.30 | 0.61 |
| Balance Sheet | ||||||
| Total Assets | 2.43B | 3.88B | 5.65B | 5.82B | 6.16B | 6.44B |
| Total Liabilities | 754M | 1.76B | 1.29B | 1.46B | 1.71B | 1.80B |
| Shareholders' Equity | 1.68B | 2.11B | 4.36B | 4.36B | 4.46B | 4.64B |
| Cash & Short-term Investments | 120M | 395M | 422M | 746M | 473M | 650M |
| Cash Flow | ||||||
| Operating Cash Flow | 196M | 215M | 35.3M | -15.8M | -185M | - |
| Capital Expenditure | 259M | 507M | 475M | 160M | 156M | 311M |
| Free Cash Flow | -62.9M | -292M | -439M | -176M | -341M | -164M |
| Ratios | ||||||
| ROE | 29.4% | 20.6% | 2.0% | 1.2% | 2.7% | 5.3% |
| ROA | 20.3% | 11.2% | 1.5% | 0.9% | 1.9% | 3.8% |
| Net Profit Margin | 31.3% | 21.1% | 4.2% | 2.9% | 6.1% | 9.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A dividends
- Dividend yield
- 0.45%
- Forward dividend
- 0.05 CNY
- Payout ratio
- 23.6%
- Ex-dividend date
- Jun 26, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 28.1M | 0.07 | 23.6% |
| 2024 | CNY 30.9M | 0.08 | 60.0% |
| 2023 | CNY 53.8M | 0.13 | 61.7% |
| 2022 | CNY 15.0M | 0.04 | 3.4% |
| 2021 | CNY 2.22M | 0.01 | 0.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A
- Insiders 60.98%
- Institutions 2.77%
- Public & others 36.25%
- Shares outstanding 400M
- Free float 159M
Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A company profile
- Company name
- Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A
- Ticker
- 301246.SHE
- ISIN
- CNE100005ZB9
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 2,258
- Fiscal year end
- December
- Address
- No.8 Hongyuan Road, Huanggang, China, 438600
- Phone
- 86 71 3510 9598
- Website
- hbhypharm.com
About Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A
Hubei Hongyuan Pharmaceutical Technology Co., Ltd., together with its subsidiaries, produces and sells pharmaceutical products in China, Asia, Europe, Africa, the Americas and internationally. The company offers active pharmaceutical ingredients, such as metronidazole, benzoyl metronidazole, dimetrizole, and acyclovir; pharmaceutical intermediates, including imidazole, glyoxylic acid, 2-methyl imidazole, 2-methyl-5-nitroimidazole, sulfate, guanine, diacetyl guanine, and diacetylacyclovir; organic chemical raw materials comprising glyoxal, and oxalic acid; and new energy materials consisting of lithium hexafluorophosphate. It also is involved in the production and sales of triamines, guanine and other products; research and development, production, and sales of pharmaceutical preparations; trading of APIS, pharmaceutical intermediates, organic chemical raw materials, etc.; fluoride salts and other fluorine-containing chemical products; contract manufacturing of pharmaceuticals, and disinfectant production and pharmaceutical wholesale, retail, etc. Hubei Hongyuan Pharmaceutical Technology Co., Ltd. was founded in 2002 and is headquartered in Huanggang, China.
Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A management
5- Mr. Shuangxi XuDirector and General Manager · born 1966
- Mr. Kefeng ZengFinancial Officer · born 1985
- Mr. Yonghua XiaoDirector, Secretary of the Board & Accounting Supervisor · born 1977
- Mr. Zhihua DengDeputy GM & Non-Independent Director · born 1970
- Mr. Siyuan ChengDeputy GM & Non-Independent Director · born 1973